Demographics
A total of 36 healthy male subjects were enrolled in the study. Age,
height, weight and BMI were 33.0 ± 6.0 years (mean ± standard
deviation), 173.7 ± 5.3 cm, 68.8 ± 7.7 kg and 22.8 ± 2.0
kg/m2, respectively. The baseline demographic
characteristics were similar across sequence groups. During the study,
one subject discontinued before drug administration due to non-treatment
emergent adverse event, and one subject withdrew consent in the first
period of the study. Therefore, 35 subjects who received study drug at
least once were included in safety assessment, and 34 subjects who
completed the whole study were included in pharmacokinetic and
pharmacodynamic assessment.